Literature DB >> 26250487

Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.

Riccardo Caccialanza1, Giovanni Palladini2, Emanuele Cereda3, Chiara Bonardi3, Paolo Milani2, Barbara Cameletti3, Lara Quarleri3, Silvia Cappello3, Andrea Foli2, Francesca Lavatelli2, Catherine Klersy4, Giampaolo Merlini2.   

Abstract

OBJECTIVE: Malnutrition is associated with mortality and impaired quality of life (QoL) in systemic immunoglobulin light-chain (AL) amyloidosis. The aim of this study was to determine whether nutritional counseling is beneficial to patients with AL.
METHODS: In this intervention study (ClinicalTrials.gov Identifier: NCT02055534), 144 treatment-naïve outpatients with AL were randomized to usual care (UC; n = 72) and nutritional counseling (NC; n = 72).
RESULTS: In the randomized population, although patients in the NC group maintained a stable body weight (weight loss [WL] = 0.6 kg; 95% confidence interval [CI], -1.0 to 2.1; P = 0.214), those in the UC group demonstrated a significant decrease (WL = 2.1 kg; 95% CI, 0.2-4.1; P = 0.003). However, the difference in weight between groups was not significant (mean WL difference = 1.6 kg; 95% CI, -0.7 to 3.9; P = 0.179). Patients in the NC group demonstrated more satisfactory energy intake (≥75% of estimated requirements, odds ratio, 2.18; 95% CI, 1.04-4.57; P = 0.048) and a significant increase in the mental component summary of QoL (Short form-36) at 12 mo (mean difference, 8.1; 95% CI, 2.3-13.9; P = 0.007), which was restored to a mean score of 53 (95% CI, 50-53), over the healthy population norms. NC was also associated with better survival (crude hazard ratio, 0.57; 95% CI, 0.35-0.94; P = 0.028).
CONCLUSIONS: In outpatients with AL, NC was helpful in preserving body weight, effective in improving mental QoL, and associated with better survival.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AL amyloidosis; Nutritional counseling; Quality of life; Survival

Mesh:

Substances:

Year:  2015        PMID: 26250487     DOI: 10.1016/j.nut.2015.04.011

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  6 in total

1.  Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population.

Authors:  Rajshekhar Chakraborty; Lisa Rybicki; Jacqulyn Tomer; Christy J Samaras; Beth M Faiman; Jason Valent; Navneet S Majhail
Journal:  Leuk Lymphoma       Date:  2019-07-05

Review 2.  Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults.

Authors:  Christine Baldwin; Marian Ae de van der Schueren; Hinke M Kruizenga; Christine Elizabeth Weekes
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

Review 3.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

Review 4.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

5.  Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy.

Authors:  Emanuele Cereda; Annalisa Turri; Catherine Klersy; Silvia Cappello; Alessandra Ferrari; Andrea Riccardo Filippi; Silvia Brugnatelli; Marilisa Caraccia; Silvia Chiellino; Valeria Borioli; Teresa Monaco; Giulia Maria Stella; Luca Arcaini; Marco Benazzo; Giuseppina Grugnetti; Paolo Pedrazzoli; Riccardo Caccialanza
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

6.  Content validation of the SF-36v2® health survey with AL amyloidosis patients.

Authors:  Michelle K White; Martha S Bayliss; Spencer D Guthrie; Kimberly P Raymond; Avery A Rizio; Kristen L McCausland
Journal:  J Patient Rep Outcomes       Date:  2017-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.